Imugene (ASX:IMU) has received a Notice of Allowance from the US Patent and Trademark Office (USPTO) for its patent application number that protects its oncolytic virotherapy CF33-CD19 and its combination with CD19 targeting CAR-T cell therapies.
The company stated that the patent protects the method of composition and method of use of Imugene’s onCARlytics technology through 2038. Exclusively licensed to Imugene, onCARlytics is a CD19-expressing oncolytic virus that enters solid tumour cells and forces them to express the CD19 protein on the cell surface, presenting a target for CD19-targeting therapies, such as CAR-T cell therapies.
Imugene's ongoing OASIS dose escalation trial of onCARlytics is being conducted at up to ten sites in the US, with approximately 40 patients proposed to participate in the trial.
Leslie Chong, Managing Director and CEO of Imugene, said, “Imugene receiving this US patent allowance for the CF33-CD19 onCARlytics platform is a crucial step forward for our IP position, with the US being the largest healthcare market in the world. This follows patent allowance in China, an equally large cell therapy market, earlier in 2025.”